Recruitment

Recruitment Status
Terminated
Estimated Enrollment
150

Inclusion Criterias

Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.
At least one failed chemotherapy treatment.
Adults >/= 18 years
Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.
At least one failed chemotherapy treatment.
Adults >/= 18 years

Summary

Conditions
Non-Squamous Non-Small Cell Lung Cancer
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criterias

Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.
At least one failed chemotherapy treatment.
Adults >/= 18 years
Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.
At least one failed chemotherapy treatment.
Adults >/= 18 years

Locations

Bucharest, 022338
Bucharest, 022338

Tracking Information

NCT #
NCT01990261
Collaborators
Not Provided
Investigators
Study Director: Clinical Trials Hoffmann-La Roche